Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Myelofibrosis. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services.

Hormones 100

Hormones Contract Manufacturing Manufacturing Development 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services.

Hormones 100

Hormones Contract Manufacturing Manufacturing Development 100

Pharmaceutical Technology

NOVEMBER 30, 2022

Manufacturing for Wegovy was also hit when a contract manufacturer in charge of syringe filling halted deliveries due to issues with good manufacturing practices. To overcome manufacturing issues, in December 2021, Novo Nordisk announced its plans to build three new manufacturing facilities.

Drugs 264

Drugs Manufacturing Hormones Clinical Trials 264

Pharmaceutical Technology

NOVEMBER 30, 2022

Manufacturing for Wegovy was also hit when a contract manufacturer in charge of syringe filling halted deliveries due to issues with good manufacturing practices. To overcome manufacturing issues, in December 2021, Novo Nordisk announced its plans to build three new manufacturing facilities.

Drugs 246

Drugs Manufacturing Hormones Clinical Trials 246

pharmaphorum

NOVEMBER 12, 2020

In 2018, it bought Element Genomics – a spin-out of Duke University in the US – to add genome-editing technologies, and has also been growing its internal exercise at its Boston R&D hub, although so far it hasn’t advanced and gene therapies into clinical development.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

Outsourcing Pharma

APRIL 17, 2023

The German and Spanish companies use their relevant expertise in conjunction to provide clients with services spanning from hit generation to pre-clinical development.

Development 52

Development Clinical Development Contract Manufacturing Manufacturing 52

Roots Analysis

FEBRUARY 27, 2024

The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization. With such a strong development ADCs pipeline, the overall ADC therapeutics market is projected to be worth $15 billion by 2030, growing at a CAGR of over 20%.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

Roots Analysis

FEBRUARY 26, 2024

In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017. Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52

The Pharma Data

AUGUST 3, 2021

The BI 767551 SARS-CoV-2 neutralizing antibody development program will be discontinued, as the current state of the pandemic makes it challenging to further progress clinical development of this antibody and make it available to patients within a reasonable time frame to contribute against the COVID-19 pandemic.

Development 52

Development Research Contract Manufacturing Sales 52

The Pharma Data

MARCH 29, 2022

“We believe in advancing health through partnerships and are excited to embark on this journey, strengthening our ability to create a positive impact on patient lives,” shared Uli Brödl, senior vice president, global clinical development and operations at Boehringer Ingelheim. Source link: [link].

Development 52

Development Contract Manufacturing Medicine Clinical Development 52

The Pharma Data

MARCH 1, 2022

We are excited to see how our technology and global biobank partnerships can transform research capabilities for Boehringer Ingelheim and deliver powerful impacts for clinical development pipelines across disease areas.”. “We Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective.

Biobanking 52

Biobanking Genome Genomics Genome Project 52

The Pharma Data

MARCH 2, 2021

This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. Financial terms of the new agreement are not disclosed.

In-Vivo 52

In-Vivo Contract Manufacturing Bioinformatics Clinical Development 52

The Pharma Data

MARCH 16, 2021

We are excited to embark on this partnership with Boehringer Ingelheim to identify potential therapeutic candidates and advance them to clinical development in order to help improve the lives of those affected by this serious mental health condition.”. Weinberger, M.D., LIBD CEO & Director. “We Boehringer Ingelheim.

Development 52

Development Contract Manufacturing Licensing Licensing 52

XTalks

JANUARY 23, 2024

Hawkins: I started my professional journey at Johnson & Johnson, gaining extensive experience in both the preclinical and clinical development of pharmaceuticals, as well as regulatory insights. Together, we developed the world’s first growth hormone receptor antagonist, Somavert (pegvisomant), targeting acromegaly.

Development 72

Development Hormones Drugs Trials 72

The Pharma Data

JUNE 2, 2022

The innovative antibodies from A*STAR can potentially enable the development of safer, more efficacious therapies as they selectively bind to antigens that are highly expressed on tumor cells but are absent on normal healthy tissues. .

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

JANUARY 27, 2021

The two-hour event will cover various topics, including an overview of the Company’s board and executive leadership, its commitment to environment, social and governance (ESG) matters, and progress updates on the Company’s critical care programs, manufacturing and distribution approach, and commercial readiness plans. About MultiStem ®.

Clinical Trials 52

Clinical Trials Clinical Trials Production Trials 52

The Pharma Data

NOVEMBER 15, 2020

MultiStem ® cell therapy is a patented regenerative medicine product candidate in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. About MultiStem ®.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

The Pharma Data

JULY 21, 2021

We believe this collaboration will create opportunity to more broadly distribute vaccine doses to people in harder-to-reach communities, especially those on the African continent.”.

Vaccine 52

Vaccine Vaccination Manufacturing Clinical Trials 52

The Pharma Data

NOVEMBER 5, 2020

Key Pipeline Progress Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications. Updates from the clinical pipeline include: Dupixent ® (dupilumab). Cost of collaboration and contract manufacturing (COCM). $.

Sales 40

Sales Production Manufacturing Antibody 40

Roots Analysis

JANUARY 27, 2025

Further, as can be observed from the figure, the microbial CMO market features the presence of small, mid-sized, large and very large companies having the required expertise to offer contract manufacturing services across the globe. Key Trends in the Microbial CMO Market A.

Marketing 40

Marketing Manufacturing Production Development 40